Falling short: Inadequate target attainment in guideline-based therapy of nontuberculous mycobacterial disease. (PubMed, medRxiv) - Oct 2, 2026 - "These include macrolides for M. abscessus and the M. avium complex (MAC), and rifampicin for M. kansasii. Bedaquiline emerged as a promising option against M. abscessus and MAC, and clofazimine against the latter, consistent with recent clinical reports. Omadacycline PTAs predict improved efficacy compared to tigecycline for patients with M. abscessus and suggest clinical utility for MAC. As is common practice for antibacterials, PTA considerations could inform NTM treatment guidelines and help select drug combinations in future trials."
Journal • Infectious Disease • Nontuberculous Mycobacterial Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis
|
|
Elsje Pienaar; Erika Bawab; Marina de Lorena Muniz Surani; Meghna Nair; Noah Strawhacker; Patricio Escalante; Thomas Dick; Trevor Jaan Shoaf; Tyler Dierckman; Véronique A Dartois
|